HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.106.036699v1 48/6/965    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zitzmann, S. Articles by Haberkorn, U. Search for Related Content PubMed PubMed Citation Articles by Zitzmann, S. Articles by Haberkorn, U.

Identification and Evaluation of a New Tumor Cell–Binding Peptide, FROP-1

¹ Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany; ² Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany; ³ Department of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany; ⁴ Forschungszentrum Dresden-Rossendorf, Dresden, Germany; and ⁵ Bayer-Schering-Pharma Research Laboratories, Berlin, Germany

Correspondence: For correspondence or reprints contact: Sabine Zitzmann, PhD, Bayer Schering Pharma Research Laboratories, Müllerstrasse 178, 13342, Berlin, Germany. E-mail: sabine.zitzmann{at}schering.de

Peptides are useful tools for the targeted delivery of radionuclides or chemotherapeutic drugs to their site of action within an organism. Given that the peptide receptor is overexpressed at the tumor, therapeutically active doses can be delivered to the tumor with reduced side effects. Because currently known peptides are restricted to a small number of tumors, new molecules and their corresponding receptors have to be identified to enlarge the spectrum of malignancies that can be diagnosed or treated using tumor-targeting peptides. Methods: A 12-amino-acid peptide phage display system was applied to identify a new peptide binding to follicular thyroid carcinoma cells. The properties of the radiolabeled peptide were assessed in binding, competition, and internalization experiments in a variety of tumor cell lines including FRO82-2 and MCF-7 cells, and the pharmacokinetic behavior of the radiolabeled peptide was evaluated in tumor-bearing mice. Peptide stability was studied in human serum. Results: After 5 selection rounds, the new peptide, FROP-1 (EDYELMDLLAYL), was identified. It showed binding to follicular thyroid carcinoma as well as anaplastic thyroid carcinoma, mammary carcinoma, cervix carcinoma, prostate carcinoma, and cell lines derived from head and neck tumors, and low affinity could be observed to control cells such as human umbilical vein endothelial cells or immortalized keratinocytes. In MCF7 cells, 78% and 86% of the bound activity was internalized after 10 and 60 min of incubation, respectively. Stability experiments in human serum showed the appearance of a degradation product after 15 min. Tumor uptake of the radioactive labeled peptide increased for 45 min in nude mouse models, reaching an accumulation level of approximately 3.6 percentage injected dose (%ID)/g for FRO82-2 tumors or approximately 3.8 %ID/g for MCF-7 tumors. Conclusion: The target of FROP-1 is most likely a molecule found generally in tumors, making this peptide highly attractive for diagnostic or therapeutic applications. However, modifications are needed to increase stability and affinity.

Key Words: tumor targeting • thyroid carcinoma • mammary carcinoma • peptide • phage display

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  

This article has been cited by other articles:

				W. Mier, S. Zitzmann, S. Kramer, J. Reed, E.-M. Knapp, A. Altmann, M. Eisenhut, and U. Haberkorn Influence of Chelate Conjugation on a Newly Identified Tumor-Targeting Peptide J. Nucl. Med., September 1, 2007; 48(9): 1545 - 1552. [Abstract] [Full Text] [PDF]